Antiphospholipid Syndrome: Clinical Trials

18 trials for Antiphospholipid Syndrome, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 completed, 6 recruiting, 2 terminated, 2 unknown. 18 Phase 2, 3 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 218Completed 6, Recruiting 6, Terminated 2, Unknown 2, Withdrawn 2
Phase 13Recruiting 2, Withdrawn 1
Phase 31Unknown 1

Follow Antiphospholipid Syndrome: new trials by email Literature Review of Antiphospholipid Syndrome trials Research Report on Antiphospholipid Syndrome

Trials (filtered) newest first · largest first

All 18 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Anifrolumab in Adults With Primary Antiphospholipid Syndrome (AnifAPS Trial)
Anifrolumab - Antiphospholipid Syndrome (APS)
Phase 2RecruitingNational and Kapodistrian University of Athens202026-04-292026-06-02
A Study to Evaluate Crovalimab in People With Antiphospholipid Syndrome (APS)
Crovalimab, Placebo, VKA - Antiphospholipid Syndrome
Phase 2WithdrawnHoffmann-La Roche2026-03-162026-03-02
Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases
anti-CD19 CAR T cell therapy - Systemic Lupus Erthematosus, Systemic Sclerosis (SSc)
Phase 1 / Phase 2RecruitingPeking University Third Hospital92025-07-012026-09-22
BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases
BCMA-CD19 CAR-T therapy - Systemic Lupus Erythematosus, Inflammatory Myopathy
Phase 2RecruitingPeking University People's Hospital502024-12-262025-04-02
Effect of Belimumab on Antibody Titers in Primary APS Patients
Belimumab+SOC, SOC - Antiphospholipid Syndrome (APS)
Phase 2RecruitingRuijin Hospital202024-04-012024-12-24
Effect of Telitacicept on Antibody Titers in Primary APS Patients
Telitacicept+SOC, SOC - Antiphospholipid Syndrome (APS)
Phase 2CompletedRuijin Hospital202023-12-012026-01-20
Anti-CD38 Antibody Treating APS With Thrombocytopenia
Anti-CD38 antibody Injection - Antiphospholipid Syndrome, Thrombocytopenia
Phase 2UnknownInstitute of Hematology & Blood Diseases Hospital, China102023-08-012025-08-05
Daratumumab in Primary Antiphospholipid Syndrome
Daratumumab - Autoimmune Disorders
Phase 1 / Phase 2RecruitingNational Institute of Allergy and Infectious Diseases (NIAID)222023-05-262026-10-21
The BeLimumab Antiphospholipid Syndrome Trial (BLAST)
Belimumab - Antiphospholipid Syndrome
Phase 2 / Phase 3UnknownUniversity of Turin, Italy152022-06-012023-01-13
Safety and Efficacy of Zanubrutinib in the Treatment of Antiphospholipid Syndrome With Secondary Thrombocytopenia
zanubrutinib - Antiphospholipid Syndrome, Thrombocytopenia
Phase 2RecruitingInstitute of Hematology & Blood Diseases Hospital, China102022-01-252025-02-24
RIvaroxaban for Stroke Patients With AntiPhospholipid Syndrome
Rivaroxaban, Warfarin - Antiphospholipid Syndrome, Systemic Lupus Erythematosus
Phase 2CompletedUniversity College, London432021-07-092026-05-22
Telitacicept in Primary APS Patients
Telitacicept - Anti Phospholipid Syndrome
Phase 2TerminatedPeking Union Medical College Hospital202021-07-012025-06-08
Study of the Efficiency of Hydroxychloroquine on the Endothelial Dysfunction and Its Vascular Consequences During the Antiphospholipid Syndrome
Hydroxychloroquine, placebo - Antiphospholipid Syndrome (APS)
Phase 2TerminatedUniversity Hospital, Rouen252016-05-172026-04-14
Eculizumab to Enable Renal Transplantation in Patients With History of Catastrophic Antiphospholipid Antibody Syndrome
Eculizumab - Antiphospholipid Antibody Syndrome, End Stage Renal Disease
Phase 2CompletedJohns Hopkins University12009-11-012020-10-26
Effects of Fluvastatin on Proinflammatory and Prothrombotic Markers in Antiphospholipid Syndrome Patients
Fluvastatin - Antiphospholipid Syndrome
Phase 2CompletedHospital for Special Surgery, New York412008-05-012018-05-01
A Pilot Study of Rituximab for the Anticoagulation Resistant Manifestations of Antiphospholipid Syndrome
Rituximab - Antiphospholipid Syndrome
Phase 2CompletedHospital for Special Surgery, New York192007-09-012017-10-31
Low-molecular-weight Heparin (LMWH) Versus Unfractionated Heparin (UFH) in Pregnant Women With Recurrent Abortion Secondary to Antiphospholipid Syndrome
enoxaparin 40mg plus low dose aspirin, Heparin calcium5,000 U twice daily plus low dose aspirin - Recurrent Abortion
Phase 2CompletedCairo University602006-06-012011-08-29
Steroids and Antiphospholipid Syndrome- Related Pregnancy Loss
Low dose steroids - Antiphospholipid Syndrome
Phase 1 / Phase 2WithdrawnImperial College London2005-10-012024-02-26

Narrower conditions

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (2)  ·  Lupus Erythematosus, Systemic (2)  ·  Myositis (2)  ·  Scleroderma, Systemic (2)  ·  Sjogren's Syndrome (2)  ·  Thrombocytopenia (2)  ·  Abortion, Habitual (1)  ·  Autoimmune Diseases (1)  ·  Behcet Syndrome (1)  ·  Brain Ischemia (1)  ·  Immunoglobulin G4-Related Disease (1)  ·  Ischemic Stroke (1)  ·  Kidney Failure, Chronic (1)  ·  Purpura, Thrombotic Thrombocytopenic (1)

Broader conditions

Immune System Diseases (18)  ·  Autoimmune Diseases (17)  ·  Blood Platelet Disorders (3)  ·  Cardiovascular Diseases (3)  ·  Connective Tissue Diseases (3)  ·  Cytopenia (3)  ·  Hematologic Diseases (3)  ·  Hemic and Lymphatic Diseases (3)  ·  Nervous System Diseases (3)  ·  Skin and Connective Tissue Diseases (3)  ·  Vascular Diseases (3)  ·  Arthritis (2)  ·  Arthritis, Rheumatoid (2)  ·  Dry Eye Syndromes (2)  ·  Eye Diseases (2)

Interventions

Aspirin (1)  ·  Enoxaparin (1)  ·  Fluvastatin (1)  ·  Hydroxychloroquine (1)  ·  Rituximab (1)  ·  Rivaroxaban (1)  ·  Steroids (1)  ·  Warfarin (1)  ·  anifrolumab (1)  ·  belimumab (1)  ·  daratumumab (1)  ·  eculizumab (1)  ·  telitacicept (1)  ·  zanubrutinib (1)

Sponsors

Hospital for Special Surgery, New York (2)  ·  Institute of Hematology & Blood Diseases Hospital, China (2)  ·  Ruijin Hospital (2)  ·  Cairo University (1)  ·  Hoffmann-La Roche (1)  ·  Imperial College London (1)  ·  Johns Hopkins University (1)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (1)  ·  National and Kapodistrian University of Athens (1)  ·  Peking Union Medical College Hospital (1)  ·  Peking University People's Hospital (1)  ·  Peking University Third Hospital (1)  ·  University College, London (1)  ·  University Hospital, Rouen (1)  ·  University of Turin, Italy (1)

Countries

China (7)  ·  United States (4)  ·  United Kingdom (2)  ·  Egypt (1)  ·  France (1)  ·  Greece (1)  ·  Italy (1)

Top investigators

Doruk Erkan, MD (2)  ·  Lei Zhang, MD (2)  ·  Ahmed M Sayed (1)  ·  Benjamin Philosophe, MD, PHD (1)  ·  Doruk Erkan, M.D., M.P.H. (1)  ·  Hannah Cohen (1)  ·  Jason Knight, M.D., Ph.D. (1)  ·  Jiuliang Zhao, M.D. (1)  ·  Raj Rai, MRCOG (1)  ·  Silvia Pierangeli, PhD (1)  ·  Usama M Fouda (1)  ·  Zhanguo Li (1)

Results publications

PMID 32358837, PMID 21251653, PMID 22269862, PMID 23124321

NIH funding

2025 (2), 2005 (1)